What should we do about Hypertriglyceridemia in coronary artery disease patients?

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 1, 2013, Pages 104-117

  Singh, Amita ^a   Schwartzbard, Arthur ^a,b   Gianos, Eugenia ^a   Berger, Jeffrey S ^a   Weintraub, Howard ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VISN3 MIRECC   (United States)

Author keywords

Cardiovascular disease; Fibrates; Niacin; Omega 3 fish oil; Triglycerides

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CYCLOSPORIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; MARINE; METFORMIN; NICOTINIC ACID; OLANZAPINE; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; PROTEINASE INHIBITOR; RETINOID; ROSIGLITAZONE; SIMVASTATIN; TACROLIMUS; TAMOXIFEN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84873079878     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0220-7     Document Type: Article

References (67)

1. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
2. Labossiere R, Goldberg I. Management of Hypertriglyceridemia. In: Davidson M, editor. In: Therapeutic Lipidology. Totowa: Humana Press; 2007. p. 201-20.
3. Hanak V, Munoz J, Teague J, et al. Accuracy of the triglycerides to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol. 2004;94:219-22.
4. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Throm. 1991;11:2-14.
5. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
6. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and Risk of Coronary Heart Disease: The Framingham Study. Ann Epidemiol. 1992;2:23-8.
7. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM) - results of follow-up at 8 years. Eur Heart J. 1998;19:A2-A11.
8. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease - an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-36.
9. Bansal S, Buring JE, Rifai N, Mora S, et al. Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. JAMA. 2007;298(3):309-16.
10. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
11. Patel A, Barzi F, Jamrozik K, et al. Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region Asia. Circulation. 2004;110:2678-86.
12. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-8.
13. Emerging Risk Factor's Collaboration. Major Lipids, Apolipoproteins and Risk of Vascular Disease JAMA 2009;302: 1993-2000.
14. Miller M, Cannon CP, Murphy SA, et al. Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol. 2008;51:724-30.
15. Faergeman O, Holme I, Fayya R, et al. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease. Am J Cardiol. 2009;104:459-63.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
17. Standards of Medical Care in Diabetes - 2011. Diab Care 2011;34:S11-S61.
18. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-8.
19. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendations for adults from the American College of Sports Medicine and the America Heart Association. Circulation. 2007;116:1081.
20. Kraus WE, Houmart JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. NEJM. 2002;347:1483.
21. Pieke B, von Eckardstein A, Gülbahçe E, et al. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. Int J Obes Relat Metab Disord. 2000;24:1286-96.
22. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med. 2002;113:13S-24S.
23. Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. 2010;21:346-51.
24. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEJM. 2005;352:1425-35.
25. The Stroke Prevention by Aggressive Reductioni n Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. NEJM 2006;355:549-559.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
27. Ridker PM, Danielson E, Francisco AH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM. 2008;359:2195-207.
28. Stein EA, Lane M, Laskarzewski P, et al. Comparison of Statins in Hypertriglyceridemia. Am J Cardiol. 1998;81:6609.
29. Bakker-Arkema RG, Davidson MH, Goldstein RJ. Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia. JAMA. 1996;275:128-33.
30. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation. 1998;98:2088-93.
31. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apoAI-mediated HDL biogenesis by enhancing transcription of ABCA1 gene in an LXR-dependent manner. Arterioscler Thromb Vasc Biol. 2005;25:1193-7.
32. Dachet C, Cavalerro E, Martin C, Girardot G, Jacotot B. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis. 1995;113:1-9.
33. Rubens HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. NEJM. 1999;341:410-8.
34. Otvos JD, Collins D, Freedman DS, et al. Low Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events And Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-63.
35. BIP Study Group. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients with Coronary Artery Disease: the Bezafibrate Infarction Prevention Study. Circulation. 2000;102:21-7.
36. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11:89-94.
37. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
38. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. NEJM. 2010;362:1563-74.
39. Scott R, O'Brien R, Fulcher G. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-8.
40. Otvos, J. The surprising AIM-HIGH results are not surprising when viewed through a particle lens. J Clin Lipid 2011;5: 368-70.
41. Vaijinath SK, Kashyap L. Mechanism of Action of Niacin. Am J Card. 2008;101:S20-6.
42. McKenney J. New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders. Arch Intern Med. 2004;164:697-705.
43. The Coronary Drug Project Research Group. Clofibrate and Niacin in Coronary Heart Disease. JAMA. 1975;231:360-81.
44. Canner PL, Berrge KG, Wenger NK, et al. Fifteen year Mortality in Coronary Drug Project Patients: long-term benefit with niacin. JACC 1986;1245.
45. The AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEJM 2011;365:2255-2267. Widely publicized clinical trial of niacin versus placebo to raise low HDL in patients with established cardiovascular disease, which was stopped early due to lack of efficacy.
46. HPS2-THRIVE: A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant. http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed August 2012.
47. Armitage, Jane. HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events. Presented at the European Society of Cardiology 2012 Congress. Munich, Germany. August 25-29, 2012.
48. Grundy DM, Vega GL, McGovern ME, et al. Diabetes Multicenter Research Group: Efficacy, safety and tolerability of once daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002;162:1568.
49. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA. 2000;284:1263.
50. Stone NJ. Fish Consumption, Fish Oil, Lipids and Coronary Heart Disease. Circulation. 1996;94:2337-40.
51. Jacobson TA, Glickstein SB, Rowe JD, Soni P. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. C Clin Lipid. 2012;6:5-18.
52. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354: 447-455.
53. Yokoyama M, Origasa H, Masunori M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-8.
54. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-67.
55. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Card. 2011;108:682-90. Initial published results of AMR101 (now Vascepa), a new purified EPA-only omega 3 fish oil for use in moderate to severe hypertriglyceridemia.
56. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin Treated Patients with Persistent High Triglycerides (from the ANCHOR Study). Am J Card. Epub July 23, 2012. Followup study of Vascepa, with results demonstrating greater triglyceride-lowering with high potency statins as well as potential reductions in LDL.
57. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT) (http://clinicaltrials.gov/ct2/show/NCT01492361. Accessed August 2012.
58. Zhou G, Myers R, Li Y. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-74.
59. Stumvoll M, Nurjhan N, Perriello G. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. NEJM. 1995;333:550-4.
60. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. NEJM. 1995;333:541-9.
61. Wuffeele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med. 2004;256:1-14.
62. Gurnell M, Savage DB, Chatterjee KK. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation. J of Clin Endo& Met. 2003;88:2412-21.
63. Ginsberg HN, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose lowering. J Cardiovasc Risk. 1999;6:337-47.
64. Van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1744-9.
65. Goldberg RB, Kendall DM, Deeg MA. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547.
66. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
67. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. NEJM. 1987;317:1237-45.